Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.07% is 23% below its 5-year average of 14.34%, near the low end of its 5-year range (5.18%–30.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.89% above its 12-month average of 10.87%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.07%.
DEBT TO ASSETS RATIO
11.07%
DEBT TO ASSETS RATIO AVG TTM
10.87%
DEBT TO ASSETS RATIO AVG 3Y
15.02%
DEBT TO ASSETS RATIO AVG 5Y
14.34%
DEBT TO ASSETS RATIO AVG 10Y
10.46%
DEBT TO ASSETS RATIO AVG 15Y
9.36%
DEBT TO ASSETS RATIO AVG 20Y
31.32%
CURRENT VS TTM AVG
+1.89%
CURRENT VS 3Y AVG
-26.29%
CURRENT VS 5Y AVG
-22.77%
CURRENT VS 10Y AVG
+5.88%
CURRENT VS 15Y AVG
+18.25%
CURRENT VS 20Y AVG
-64.66%
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 597 covered companies
CURRENT VS SECTOR MEDIAN
+10970.32%
vs the sector median at left
Abeona Therapeutics Inc.
Market Cap
$281.84M
Debt to Assets Ratio
11.07%
TTM Avg
10.87%
3Y Avg
15.02%
5Y Avg
14.34%
Market Cap
$281.92M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.20M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$274.71M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$274.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$289.59M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.17M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.16M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abeona Therapeutics Inc. (ABEO) | $281.84M | 11.07% | 10.87% | 15.02% | 14.34% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 0.02% | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $286.20M | 0.03% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $274.71M | 0.04% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.61M | 0.00% | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.59M | 0.01% | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | 0.29% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.01% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.30M | 0.00% | N/A | N/A | N/A |
Debt/Assets
11.1%
Debt/Equity
0.16
Current Ratio
6.63
Interest Coverage
-23.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 11.07% |
| 2026-03-31 | 11.67% |
| 2025-12-31 | 11.37% |
| 2025-09-30 | 10.43% |
| 2025-06-30 | 9.78% |
| 2025-03-31 | 24.13% |
| 2024-12-31 | 21.16% |
| 2024-09-30 | 19.16% |
| 2024-06-30 | 17.29% |
| 2024-03-31 | 30.96% |
| 2023-12-31 | 8.44% |
| 2023-09-30 | 8.61% |
| 2023-06-30 | 11.16% |
| 2023-03-31 | 13.72% |
| 2022-12-31 | 11.88% |
| 2022-09-30 | 21.40% |
| 2022-06-30 | 19.09% |
| 2022-03-31 | 16.48% |
| 2021-12-31 | 11.78% |
| 2021-09-30 | 5.18% |
| 2021-06-30 | 6.28% |
| 2021-03-31 | 5.99% |
| 2020-12-31 | 5.77% |
| 2020-09-30 | 5.64% |
| 2020-06-30 | 5.62% |
| 2020-03-31 | 4.41% |
| 2019-12-31 | 3.56% |
| 2019-09-30 | 26.74% |
| 2019-06-30 | 24.09% |
| 2019-03-31 | 23.24% |
| 2018-12-31 | 17.20% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 5.39% |
| 2016-03-31 | 5.17% |
| 2015-12-31 | 5.00% |
| 2015-09-30 | 4.47% |
| 2015-06-30 | 5.20% |
| 2015-03-31 | 30.49% |
| 2014-12-31 | 26.53% |
| 2014-09-30 | 89.29% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 222.85% |
| 2012-06-30 | 112.84% |
| 2012-03-31 | 86.05% |
| 2011-12-31 | 72.66% |
| 2011-09-30 | 247.75% |
| 2011-06-30 | 108.59% |
| 2011-03-31 | 79.99% |
| 2010-12-31 | 62.71% |
| 2010-09-30 | 241.33% |
| 2010-06-30 | 151.72% |
| 2010-03-31 | 105.87% |
| 2009-12-31 | 347.44% |
| 2009-09-30 | 203.33% |
| 2009-06-30 | 233.94% |
| 2009-03-31 | 151.77% |
| 2008-12-31 | 151.64% |
| 2008-09-30 | 95.59% |
| 2008-06-30 | 79.48% |
| 2008-03-31 | 74.81% |
| 2007-12-31 | 60.82% |
| 2007-09-30 | 483.03% |
| 2007-06-30 | 451.16% |
| 2007-03-31 | 334.17% |
| 2006-12-31 | 223.05% |
| 2006-09-30 | 248.95% |
| 2006-06-30 | 209.44% |
| 2006-03-31 | 149.00% |
| 2005-12-31 | 107.33% |
| 2005-09-30 | 209.83% |
| 2005-06-30 | 178.54% |
| 2005-03-31 | 140.46% |
| 2004-12-31 | 125.73% |
| 2004-09-30 | 102.99% |
| 2004-06-30 | 89.32% |
| 2004-03-31 | 76.43% |
| 2003-12-31 | 121.59% |
| 2003-09-30 | 109.67% |
| 2003-06-30 | 87.53% |
| 2003-03-31 | 87.01% |
| 2002-12-31 | 77.07% |
| 2002-09-30 | 75.04% |
